Peijia Medical Ltd. (HK:9996) has released an update.
Peijia Medical Ltd. has announced the successful completion of the first compassionate use treatment with its TaurusTrio TAVR system in Hong Kong, targeting severe aortic regurgitation. The company recently finished patient enrollment for its clinical trial in China and is moving towards commercializing the system pending regulatory approval. This development could provide significant opportunities in the medical device market for investors.
For further insights into HK:9996 stock, check out TipRanks’ Stock Analysis page.
